Literature DB >> 7103449

Penetration of cefoxitin into cerebrospinal fluid of infants and children with bacterial meningitis.

W E Feldman, S Moffitt, N S Manning.   

Abstract

Three consecutive doses of 75 mg of cefoxitin per kg were given intravenously every 6 h (225 mg/kg), in addition to penicillin or ampicillin, to 24 patients on days 4 and 5 and 9 and 10 of therapy for meningitis. Haemophilus influenzae b was isolated from cerebrospinal fluid (CSF) of 21 patients, Streptococcus pneumoniae from 2 patients, and Neisseria meningitidis from 1 patient. The median minimal inhibitory and bactericidal concentrations of cefoxitin for 16 isolates of H. influenzae b were 0.312 and 0.625 micrograms/ml, respectively. Sixteen of 18 isolates of H. influenzae b and S. pneumoniae were killed by 2.5 micrograms of cefoxitin per ml. Mean levels in CSF peaked at 1 h at 6 and 4.9 micrograms/ml on days 5 and 10, respectively. CSF levels on days 5 and 10 were greater than or equal to twice the median minimal inhibitory and bactericidal concentration in 20 and 18 patients, respectively. However, bacterial levels in CSF were greater than or equal to 2.5 micrograms/ml in only 11 of 23 patients on days 5 and 10. No significant adverse effects were found. These data indicate that at this dosage, cefoxitin may not reach levels in the CSF required for killing all susceptible strains of H. influenzae b and S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7103449      PMCID: PMC181916          DOI: 10.1128/AAC.21.3.468

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Interpretation of isotopic data obtained from blood-borne compounds.

Authors:  E Gurpide; J Mann
Journal:  J Clin Endocrinol Metab       Date:  1970-06       Impact factor: 5.958

2.  Rapid penicillinase paper strip test for detection of beta-lactamase-producing Haemophilus influenzae and Neisseria gonorrhoeae.

Authors:  J H Jorgensen; J C Lee; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

3.  Clinical and bacteriological evaluation of cefoxitin therapy in children.

Authors:  J A Jacobson; J I Santos; W M Palmer
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  Comparative activities of cefotaxime, a new cephalosporin derivative, and of selected beta-lactam antibiotics against Haemophilus species.

Authors:  H J Dabernat; A Buu-Hoï-Dang Van; C Delmas; R Bauriaud
Journal:  Ann Microbiol (Paris)       Date:  1979 May-Jun

5.  Use of cefoxitin, new cephalosporin-like antibiotic, in the treatment of aerobic and anaerobic infections.

Authors:  S R Nair; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

6.  Results of a clinical trial of cefoxitin, a new cephamycin antibiotic.

Authors:  R V McCloskey
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

7.  Cefoxitin, a semisynthetic cephamycin antibiotic: susceptibility studies.

Authors:  H Wallick; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

8.  Microbioassay of antimicrobial agents.

Authors:  H J Simon; E J Yin
Journal:  Appl Microbiol       Date:  1970-04

9.  Cefoxitin penetration into cerebrospinal fluid in patients with purulent meningitis.

Authors:  P A Galvao; A V Lomar; W Francisco; C V de Godoy; R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

10.  Cefoxitin: clinical evaluation in thirty-eight patients.

Authors:  P N Heseltine; D F Busch; R D Meyer; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

View more
  2 in total

Review 1.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 2.  Rationale for optimal dosing of beta-lactam antibiotics in therapy for bacterial meningitis.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.